Frontiers in Clinical Drug Research - Hematology : (Record no. 23155)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 09047nam a22004933i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC6424224 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240724114750.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2020 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9789811469558 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9789811469534 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC6424224 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL6424224 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)1227390671 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RB145 .R346 2020 |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.15 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Atta-ur-Rahman. |
| 245 10 - TITLE STATEMENT | |
| Title | Frontiers in Clinical Drug Research - Hematology : |
| Remainder of title | Volume 4. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Singapore : |
| Name of producer, publisher, distributor, manufacturer | Bentham Science Publishers, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2020. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2020. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (267 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 490 1# - SERIES STATEMENT | |
| Series statement | Frontiers in Clinical Drug Research - Hematology Series |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Preface -- List of Contributors -- TRP Channels: Potential Therapeutic Targets in Blood Disorders -- Amritlal Mandal* -- INTRODUCTION -- TRP CHANNELS IN BLOOD DISORDERS -- TRP Channels and Abnormalities in RBCs -- Sickle Cell Disease (SCD) -- TRP Channels in Platelets Related Disorders -- TRPML and Iron-deficiency Anaemia -- TRPM6 in Dysregulated Blood and Serum Mg2+ Homeostasis -- TRP Channels and Hematological Malignancies -- TRPM Channels -- TRPM1 -- TRPM2 -- TRPM4 -- TRPM5 -- TRPM7 -- TRPM8 -- TRPV Channels -- TRPV1 -- Leukemia Cell Lines -- Adult T-Cell Leukemia (ATL) -- Multiple Myeloma (MM) -- TRPV2 -- TRPV5 and TRPV6 -- TRPC Channels -- TRPC1 -- TRPC2, TRPC3 and TRPC6 -- TRPC7 -- TRPP Channels -- CONCLUSIONS AND FUTURE DIRECTION -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Hypercoagulable States: Clinical Symptoms, Laboratory Markers and Management -- Pusparini Pusparini1 and Adi Hidayat2,* -- INTRODUCTION -- CLINICAL SYMPTOMS -- Venous Thromboembolism (VTE) -- Pathophysiology -- Clinical Presentation -- Evaluation -- Arterial Thromboembolism -- Recurrent Venous Thromboembolism -- Risk Factors of Recurrent VTE -- RISK FACTORS/PREDISPOSING FACTORS -- Management -- HYPERCOAGULABLE DISORDERS -- Antiphospholipid Syndrome -- Lupus Anticoagulant Testing -- Anticardiolipin and β2GPI Antibody Testing -- Management -- Venous Thrombotic Events -- Direct Oral Anticoagulants (DOACs) -- Non-Anticoagulant Treatment of Thrombotic APS -- Factor V Leiden Mutation and Activated Protein C Resistance -- Factor V Leiden (FVL) -- Management -- Prothrombin Gene G20210A Mutations -- Management -- Protein C Deficiency -- Pathophysiology -- Management -- Protein S Deficiency -- Pathophysiology -- Epidemiology -- Laboratory Tests. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Management -- Antithrombin Deficiency -- Laboratory Tests -- Hyperhomocysteinemia -- Management -- Elevated Factor VIII -- Dysfibrinogenemia -- ALGORITHMIC APPROACH TO LABORATORY TESTING -- Patient Selection -- Reason to Test -- The "4P" Approach -- Whom to Test -- Whom Not to Test -- Points to Consider in Requests for Laboratory Examinations -- MANAGEMENT -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Advanced Applications of Gene Therapy in the Treatment of Haematologic Disorders -- Mayasah Al-Nema and Anand Gaurav* -- INTRODUCTION -- GENE THERAPY TECHNIQUES USED IN THE TREATMENT OF BLOOD DISORDERS -- Gene Delivery Viral Vectors -- Haemophilia -- β-Haemoglobinopathies -- Genome Editing Technology (CRISPR-Cas9) -- How Does CRISPR Work in Bacteria? -- Application of CRISPR-Cas9 in β-Haemoglobinopathies and Fanconi Anaemia -- Chimeric Antigen Receptor (CAR) T-Cell Therapy -- CAR T-Cell Therapy for Haematological Malignancies -- CAR Modified-Hematopoietic Stem Cells -- CURRENT CHALLENGES AND FUTURE OUTLOOK -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Ferroptosis - Importance and Potential Effects in Hematological Malignancies -- Gabriel Ignacio Aranalde1,2,* -- INTRODUCTION -- MAIN FEATURES OF DIFFERENT PROGRAMMED CELL DEATH PROCESSES -- Introduction -- Apoptosis -- Autophagy -- Necroptosis -- Pyroptosis -- Ferroptosis -- CELLULAR SIGNALING PATHWAYS -- Lipid Metabolism -- Amino Acid Metabolism -- Cystine Pathway -- Transsulfuration Pathway -- Mevalonate Pathway -- Nicotinamide Adenine Dinucleotide Phosphate Pathway -- Iron Metabolism -- MAPK Pathway -- ROS Metabolism -- ROS Production Pathways -- ROS Sources -- CONTROL OF FERROPTOSIS: SENSITIVITY MODULATION -- Inducers -- Erastin -- Sulfasalazine -- Sorafenib -- RSL3 and RSL5. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Buthioninesulfoximine -- Acetaminophen -- Lanperisone -- Artesunate -- Glutamate -- ML-162 -- Diphenyleneiodonium Compounds -- Cystine/Cysteine Deprivation -- Cisplatin -- FIN56 -- FINO2 -- Statins -- Cysteinase -- Silica-Based Nanoparticles -- Ferric Ammonium Citrate -- Trigonelline -- Brusatol -- Inhibitors -- Vitamin E -- Ferrostatin -- Liproxstatin-1 -- Zileuton -- Deuterated Polyunsaturated Fatty Acids -- Synthetic Antioxidants -- Coenzyme Q10 -- Deferoxamine -- Glutaminolysis Inhibition -- Cycloheximide -- Beta-Mercaptoethanol -- Dopamine -- Selenium -- Inhibitors of Dipeptidyl Peptidase 4 -- Dual compounds -- Histone Deacetylase Inhibitors -- Positive Regulators -- p53 -- RAS -- TFR1 -- VDAC2/3 -- CARS -- NOX -- microRNA -- Negative Regulators -- Nrf2 -- GPX4 -- System Xc- -- microRNA -- HSPB1 -- FERROPTOSIS AND CANCER -- Diffuse Large B-cell Lymphoma -- T-Cell Lymphoma -- Leukaemia -- Multiple Myeloma -- Hepatocellular Carcinoma -- Colorectal Cancer -- Gastric Cancer -- Prostate Adenocarcinoma -- Ovarian Cancer -- Breast Cancer -- Pancreatic Cancer -- Lung Carcinoma -- Renal Carcinoma -- FERROPTOSIS AND NON-MALIGNANCIES DISEASES -- Intracerebral Haemorrhage -- Cardiomyopathy -- Hepatopathy -- Acute Kidney Failure -- CONCLUSION -- ABBREVIATIONS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Clinical Application of Liquid Biopsy in Solid Tumor HCC: Prognostic, Diagnostic and Therapy Monitoring Tool -- Bushra Ijaz1,*, Sidra Rehman2, Hafiza Ishrat Fatima1 and Faiza Shams1 -- INTRODUCTION -- Presence of Tumor Derived Components in Plasma -- History and Biology of Liquid Biopsy -- CIRCULATING TUMOR CELLS (CTCS) -- CHARACTERISTICS AND DETECTION TECHNIQUES OF CIRCULATING TUMOR CELLS -- Enrichment Methods -- Magnetic Activated Cell Sorting (MACS) -- Density-based Cell Separation -- Size-based Cell Separation. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Magnetophoretic Mobility Based Cell Separation -- Dielectrophoretic (DEP) CTCs Separation -- Affinity Chromatography CTCs Separation -- Detection Techniques -- Direct Detection using a Line-Confocal Microscope -- Detection of CTCs by SERS Nanoparticles -- Fluorescence Assisted Cell Sorting (FACS) -- Nucleic-acid-based Detection -- CTCs in HCC Patients -- CIRCULATING TUMOR DNA (CTDNA) -- Characteristics and Detection Tools -- Real Time PCR Based Methods -- Methylation-Specific PCR -- Droplet Digital PCR (ddPCR) -- BEAMing (Beads Emulsion, Amplification Magnetic) -- Next-Generation Sequencing (NGS) -- Tagged-Amplicon Deep Sequencing (TAm-seq) -- Cancer Personalized Profiling By Deep Sequencing (Cappseq) -- Safe-Sequencing System (Safe-SeqS) -- Ion Torrent -- Personalized Analysis of Rearrangement Ends (PARE) -- CTDNA in HCC Patients -- Point Mutations -- DNA Methylation -- Copy Number Variation (CNV) -- Microsatellite Alterations -- Chromosomal Rearrangements -- Viral Infection -- EXOSOME AND EXOSOMAL DNA -- Exosome Biogenesis -- Exosome Isolation and Characterization -- Exosomes in HCC Patients -- Induction of HCC Metastasis by Exosomes -- Exosomes as Diagnostic Markers for HCC -- Exosomes Contribute in Immune Regulation of HCC Cells -- Applications of liquid biopsy in other Diseases -- CHALLENGES IN THE APPLICATION OF LIQUID BIOPSY -- Challenges of CTCs -- Challenges in the Analysis of ctDNA -- Challenges in The Analysis of Exosomes -- CONCLUSION -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Subject Index -- Back Cover. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Blood-Diseases. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Pharmacology. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Hematology. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Atta-ur-Rahman |
| Title | Frontiers in Clinical Drug Research - Hematology: Volume 4 |
| Place, publisher, and date of publication | Singapore : Bentham Science Publishers,c2020 |
| International Standard Book Number | 9789811469534 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
| Uniform title | Frontiers in Clinical Drug Research - Hematology Series |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=6424224">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=6424224</a> |
| Public note | Click to View |
No items available.